Cytokinetics to Hold Annual Meeting of Stockholders
May 05 2021 - 4:00PM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its
Annual Meeting of Stockholders will be held on Wednesday, May 12,
2021 at 10:30 AM Pacific Time at the Company’s headquarters, 280
East Grand Avenue, South San Francisco, CA. Immediately after the
conclusion of the Annual Meeting of Stockholders, Robert I. Blum,
President and Chief Executive Officer, is scheduled to present an
overview of Cytokinetics’ performance.
Due to the COVID-19 pandemic, Cytokinetics will
be taking certain precautionary measures to ensure the health and
safety of those in attendance. Attendees will be required to wear a
face mask, comply with social distancing guidelines and pass a
touchless, infrared temperature check prior to entering
Cytokinetics’ facilities. Anyone exhibiting fever or flu-like
symptoms will not be allowed entry to the building.
Stockholders of record at the close of business
on March 22, 2021 are entitled to vote at Cytokinetics’ Annual
Meeting of Stockholders or to attend in person and submit questions
to management. Stockholders wishing to vote must attend the meeting
in person or submit a valid proxy card by mail, telephone or
internet by 11:59 PM Eastern Time on May 11, 2021, in accordance
with instructions contained in our Proxy Statement and our Notice
of Internet Availability of Proxy Materials for the 2021 Annual
Meeting of Stockholders.
Interested parties may access the live webcast
of the Annual Meeting of Stockholders and the subsequent
presentation by visiting the Investors & Media section of
Cytokinetics’ website at www.cytokinetics.com. The live audio of
the conference call can also be accessed by telephone by dialing
either (866) 999-CYTK (2985) (United States and Canada) or (706)
679-3078 (international) and typing in the passcode
3387197.
An archived replay of the webcast will be
available via Cytokinetics’ website until May 26, 2021. The replay
will also be available via telephone by dialing (855) 859-2056
(United States and Canada) or (404) 537-3406 (international) and
typing in the passcode 3387197 from May 12, 2021 at 1:30 PM Pacific
Time until May 26, 2021.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is preparing for regulatory
interactions for omecamtiv mecarbil, its novel cardiac muscle
activator, following positive results from GALACTIC-HF, a large,
international Phase 3 clinical trial in patients with heart
failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3
clinical trial of omecamtiv mecarbil. Cytokinetics is also
developing CK-274, a next-generation cardiac myosin inhibitor, for
the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics is also
developing reldesemtiv, a fast skeletal muscle troponin activator
for the potential treatment of ALS and other neuromuscular
indications following conduct of FORTITUDE-ALS and other Phase 2
clinical trials. The company is preparing for the potential
advancement of reldesemtiv to a Phase 3 clinical trial in ALS.
Cytokinetics continues its over 20-year history of pioneering
innovation in muscle biology and related pharmacology focused to
diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and
follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserSenior Vice
President, Corporate Communications, Investor Relations(415)
290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024